Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910882 · ClinicalTrials.gov registry record · Phase 2
PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
A Phase 2 study, sponsored by Scripps Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02910882: Clinical Trial Phase 2 study, sponsored by Scripps Health.
NCT02910882 is a Phase 2 study that was terminated before completion, run by Scripps Health. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02910882, a Phase 2 study, was terminated before completion, sponsored by Scripps Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a single arm phase II trial assessing the potential activity of combination PEGPH20 plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic adenocarcinoma.
Primary Outcome
Adverse events will be assessed weekly, from Day1 Treatment through up to 8 weeks after the end of treatment. Safety will be assessed during the study by evaluation of AEs, clinical safety laboratory tests (hematology, blood chemistry (including C-reactive protein \[CRP\]), coagulation, urinalysis, and PEGPH20 immunogenicity), vital signs, 12-lead ECGs, and physical examinations. The severity of AEs will be graded by Investigators using the National Cancer Institute (NCI) Common Terminology Cri
Interventions
- DRUG Gemcitabine
- RADIATION Radiation
- DRUG PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-01-03 |
| Est. Completion | 2018-08-31 |
| Phase | Phase 2 |
Why NCT02910882 stopped before completion
NCT02910882 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02910882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02910882 about?
NCT02910882 is a clinical study titled "PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer". This is a single arm phase II trial assessing the potential activity of combination PEGPH20 plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic adenocarcinoma.
What is the current status of trial NCT02910882?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2017-01-03. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT02910882?
The interventions under investigation include: Gemcitabine (DRUG), Radiation (RADIATION), PEGylated Recombinant Human Hyaluronidase (PEGPH20) (DRUG).
Who is sponsoring clinical trial NCT02910882?
This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02910882's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI